摘要
目的研究阿托伐他汀与阿仑膦酸钠联合用药对于治疗骨质疏松症及降低并发症风险的作用。方法将129例分为阿仑膦酸钠单药组(65例)以及阿仑膦酸钠与阿托伐他汀联合用药组(64例),分别给予阿仑膦酸钠加钙尔奇D片口服以及阿仑膦酸钠+阿托伐他汀+钙尔奇D片联用口服。12个月后比较两组间依据腰部疼痛评分而得出的总有效率,观测骨密度的变化并分析骨质疏松治疗后新增颈动脉内中膜增厚病例发生情况。结果治疗12个月后,联合用药组基于疼痛评分的总有效率与阿仑膦酸钠单药组间差异无统计学意义,联合用药组骨密质值年变化率(11.26±2.58)%大于阿仑膦酸钠单药组(10.07±2.75)%(P<0.05),联合用药组治疗后新增颈动脉内中膜增厚病例(4例)少于阿仑膦酸钠组(14例)(P<0.05)。结论阿仑膦酸钠、阿托伐他汀联用,对于治疗骨质疏松症具有更好疗效,并且可有效降低动脉粥样硬化并发症的风险,联合用药优于阿仑膦酸钠单一用药。
Objective To study the effects of atorvastatin and alendronate used together in the treatment of osteoporosis, and their effectiveness in reducing the risk of complications. Methods 129 patients were divided into the alendronate group （ n=65 ） who had alendronate plus caltrate D through the mouth and the alendronate and atorvastatin group （ n=64 ） who had alendronate ＋ atorvastatin ＋ caltrate D through the month. 12 months later, the total effective rate was compared between the 2 groups based on the lumbar pain scores. The bone density changes were observed, and the occurrence of new cases with increased carotid artery intima-media thickness was analyzed after the treatment of osteoporosis. Results After 12 months of treatment, the differences in the total effective rate based on the lumbar pain scores were not statistically significant between the drug combination group and the single alendronate group. The annual gradient of bone density values in the drug combination group was （ 11.26＋2.58 ） %, which was greater than （ 10.07-4-2.75 ） % in the single alendronate group （ P〈0.05 ）. There were 4 new cases with increased carotid artery intima-media thickness in the drug combination group after the treatment, and while there were 14 new cases in the single alendronate group （ P〈0.05 ）. Conclusions The efficacy of combined usage of alendronate and atorvastatin is better than the single usage of alendronate in the treatment of osteoporosis, and the risk of the complication of atherosclerosis can be effectively reduced.
出处
《中国骨与关节杂志》
CAS
2014年第1期54-57,共4页
Chinese Journal of Bone and Joint
